DermTech Announces Appointment Of General Counsel

DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Ray Akhavan to the role of General Counsel.
Publish date:

DermTech, Inc. (DMTK) - Get Report ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Ray Akhavan to the role of General Counsel. Akhavan will serve on the executive leadership team and have responsibility for all legal, intellectual property and compliance matters.

"Ray is the perfect fit for DermTech's general counsel role given his balanced experience in medical and consumer genomics, and his foundation in science and intellectual property law," commented John Dobak, M.D., CEO of DermTech.

Akhavan has more than 16 years of experience that includes private practice at a prominent international law firm, as well as with leading companies in consumer genomics and cancer diagnostics. Most recently, Akhavan served as Associate General Counsel and Chief IP Counsel at Ancestry, and prior to that as General Counsel and Chief IP Counsel at Caris Life Sciences. Akhavan's experience also includes working as a research biologist in the National Institutes of Health, and as a patent examiner at the United States Patent & Trademark Office. Akhavan was awarded a J.D. from Washington College of Law at American University and an M.S. in Molecular Biology from George Mason University.

Akhavan commented, "I'm very excited to join DermTech at this pivotal time. I look forward to working with the team to maximize DermTech's potential in the genomic diagnostic space, currently focusing on early non-invasive detection of melanoma and other skin cancers using innovative cutting-edge technology."

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech's mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech's investor relations site at:

Forward-Looking Statements:

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech's products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech's ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech's tests; (4) the reimbursement of DermTech's tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech's products; (6) DermTech's ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech's products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the "Risk Factors" section of the most recent Quarterly Report on Form 10‑Q filed by DermTech with the Securities and Exchange Commission (the "SEC"), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based .

View source version on